We have observed
16 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
December 16, 2012).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
AGONIST DR5 BINDING POLYPEPTIDES
HUMAN ANTIBODIES AGAINST IL13 AND THERAPEUTIC USES
CXCR2 BINDING POLYPEPTIDES
FUSION PROTEINS FOR TREATING METABOLIC DISORDERS
TREATMENT OF FIBROSIS
BIOMARKERS ASSOCIATED WITH CDK INHIBITORS
METHODS OF TREATING FGF21-ASSOCIATED DISORDERS
COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO
COMPOSITIONS AND METHODS THAT UTILIZE A PEPTIDE TAG THAT BINDS TO HYALURONAN
PEPTIDES AND COMPOSITIONS FOR TREATMENT OF JOINT DAMAGE
NOTCH2 BINDING MOLECULES FOR TREATING RESPIRATORY DISEASES
MARKERS FOR ISOCITRATE DEHYDROGENASE INHIBITORS
PULMONARY HYPERTENSION BIOMARKER